Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson’s disease  by Carbutt, Sophia et al.
Neuroscience Letters 594 (2015) 66–69
Contents lists available at ScienceDirect
Neuroscience Letters
journa l homepage: www.e lsev ier .com/ locate /neule t
Research article
Variation in complement protein C1q is not a major contributor to
cognitive impairment in Parkinson’s disease
Sophia Carbutta, Jennifer Duffa, Alison Yarnallb, David J. Burnb, Gavin Hudsona,∗
a Mitochondrial Research Group, University of Newcastle Upon Tyne, United Kingdom
b Institute for Ageing and Health, University of Newcastle Upon Tyne, United Kingdom
h i g h l i g h t s
• Cognitive decline is a strong hallmark of PD.
• Genetic variation in C1Q – does not account for the cognitive decline seen in PD.
• Genetic variation in C1Q – is unlikely to contribute to PD aetiology.
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a b s t r a c t
Traditional dogma regarding the brain as an immune exempt organ has changed in recent years. New
research has highlighted the role of the classical complement cascade in both synaptic elimination and
function, driven largely by the role of the pathway initiating protein C1q. Given the links between C1q
and cognitive function we assessed the genetic variability of the C1q encoding genes: C1QA, C1QB and
C1QC between PD patients and matched controls. Despite a strong link between C1Q/cognitive decline
and PD/cognitive decline we were unable to ﬁnd a link between common C1Q variation and PD. We
conclude that common C1Q-A/B/C genetic variation is unlikely to contribute to cognitive decline or the
missing heritability in PD.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cognitive impairment is rapidly becoming a signiﬁcant health
risk in an already aging population [3]. Mild cognitive impairment
(MCI), the transitional state between normality and dementia, has
risen in recent years with 10–15% of individuals progressing to
Alzhemiers-type dementia. In addition,MCI has become aprognos-
ticmarker inParkinson’s disease (PD),wheredementia is a frequent
complication [21].
Cognitive decline, mediated through synapse elimination, is a
hallmark of normal ageing yet remains poorly understood. Synapse
elimination, primarily a developmental process, is an increasing
feature in a number of neurodegenerative diseases, where it is
thought that re-inactivation of the developmental synapse elim-
ination mechanism leads to disease [16]. Complement proteins
are expressed in neurons and glia and are localised to devel-
oping synapses during synaptic remodelling [17]. C1q, the ﬁrst
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subcomponent of the C1 complex of the classical pathway of
complement activation is critical to synapse elimination and con-
nectivity [17]; moreover C1q has been shown to mediate CNS
synapse formation and contribute to neuroprotection in the CNS
[2]. This is supported by recent evidence that speciﬁc components
of the complement cascade, including C1q, are up-regulated and
localised to synapses prior to neuronal loss in Alzheimer’s dis-
ease (AD) and other brain diseases [2] . At the genetic level, C1q
is encoded by three genes: C1QA, C1QB and C1QB, and studies have
linked common variation in C1q- primarily to systemic lupus ery-
thematosus [13]. However, associated phenotypes have expanded
to include; rheumatoid arthritis [18], schizophrenia [22], amy-
loidotic polyneuropathy [5], cancer metastasis[1].
Despite extensive study, the genetic causes of PD remain largely
elusive. Given the link between cognitive impairment and C1q acti-
vation, reported synaptic pathology in PD [11], and the role of C1Q
genetic variation in age-related neurological disorders, we inves-
tigated the role of common C1Q genetic variation on PD cognitive
decline and aetiology. Given that PD progression may not be lim-
ited to the post-synaptic neuron, we hypothesise that variation in
http://dx.doi.org/10.1016/j.neulet.2015.03.048
0304-3940/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Analysis of rs172378 (C1QA) and rs15940 (C1QC) genotypes onmean baseline variables (where; SD is standard deviation, P is ANOVA probability, A is affected, U is unaffected
and Comb. is combined, MMSE is mini-mental state exam score, UPDRS is the uniﬁed Parkinson’s disease rating scale, MoCA is the Montreal cognitive assessment score, PoA
is power of attention, PRM is pattern recognition memory testing and SRM is spatial recognition memory testing).
Mean (SD)
Variable rs172378 Group AA AG GG P
MMSE AA v AG v GG A 28.8 (1.1) 28.4 (1.5) 28.8 (1.2) 1.4×10−1
U 28.9 [1.3] 29.2 [1.0] 28.9 [1.2] 5.6×10−1
Comb. 28.9 [1.2] 28.7 [1.4] 28.9 [1.2] 4.8×10−1
UPDRS AA v AG v GG A 28.7 [13.4] 25.7 [10.8] 27.5 [13.0] 3.7×10−1
U – – – –
Comb. – – – –
MoCA AA v AG v GG A 25.5 [3.4] 24.8 [3.7] 25.2 [3.9] 6.9×10−1
U 26.9 [2.5] 27.0 [2.5] 26.8 [2.3] 9.8×10−1
Comb. 26.1 [3.1] 25.7 [3.5] 25.9 [3.5] 5.8×10−1
PoA AA v AG v GG A 1375.0 (255.6) 1390.9 (176.3) 1346.2 (214.3) 6.7×10−1
U 1313.2 (161.2) 1242.2 (101.5) 1264.6 (108.4) 5.8×10−2
Comb. 1347.9 (220.4) 1341.4 (170.2) 1316.8 (185.7) 7.1×10−1
PRM AA v AG v GG A 2303.3 (785.8) 2729.1 (2735.1) 2400.8 (816.7) 4.8×10−1
U 2288.4 (447.8) 2323.6 (486.3) 2316.2 (725.3) 9.5×10−1
Comb. 2296.5 (649.9) 2587.6 (2227.9) 2370.3 (775.5) 4.1×10−1
SRM AA v AG v GG A 2265.0 (840.7) 2802.3 (2221.0) 2514.0 (1072.7) 2.2×10−1
U 2352.4 (595.4) 2282.4 (528.5) 2123.2 (410.4) 4.1×10−1
Comb. 2305.1 (736.1) 2620.9 (1831.0) 2372.9 (904.1) 2.4×10−1
Mean (SD)
Variable rs15940 CC CT TT P
MMSE CC v CT v TT A 28.6 [1.3] 28.5 [1.5] 28.8 [1.2] 7.8×10−1
U 28.9 [1.3] 29.3 [1.0] 29.0 [1.1] 3.8×10−1
Comb. 28.7 [1.3] 28.8 [1.4] 28.8 [1.2] 9.1×10−1
UPDRS CC v CT v TT A 27.2 [12.9] 24.5 [9.5] 35.5 [12.1] 1.8×10−2
U – – – –
Comb. – – – –
MoCA CC v CT v TT A 25.0 [3.7] 25.3 [3.4] 25.3 [4.4] 9.1×10−1
U 26.7 [2.7] 27.8 [1.9] 25.5 [1.8] 4.9×10−2
Comb. 25.7 [3.4] 26.3 [3.1] 25.3 [3.7] 3.1×10−1
PoA CC v CT v TT A 1380.9 (233.9) 1377.7 (162.3) 1363.0 (218.0) 9.6×10−1
U 1287.1 (154.2) 1262.5 (106.9) 1269.8 [80.6] 7.2×10−1
Comb. 1345.9 (212.2) 1331.3 (152.8) 1331.9 (186.3) 8.5×10−1
PRM CC v CT v TT A 2320.4 (737.2) 2920.6 (3429.5) 2600.1 (871.4) 2.6×10−1
U 2395.4 (545.9) 2196.9 (401.5) 1947.8 (213.1) 5.2×10−2
Comb. 2350.0 (667.3) 2617.4 (2638.6) 2408.2 (792.0) 4.9×10−1
SRM CC v CT v TT A 2368.1 (817.7) 2868.3 (2758.2) 2906.2 (1289.3) 2.1×10−1
U 2315.9 (546.6) 2299.8 (564.0) 1989.5 (445.8) 4.4×10−1
Comb. 2347.5 (721.3) 2630.1 (2141.9) 2636.6 (1173.8) 2.9×10−1
C1Q-A/B/C may modulate PD cognitive function and may provide
an insight into the missing heritability.
2. Materials and methods
2.1. Subjects
Wecompared158 community based caseswith PD fulﬁllingUK-
PD Society brain bank criteria for the diagnosis of PD [7] (mean age
66.0 years, SD=8.04, 61% male) from the North East of England to
an ethnically age and gendermatched control group (N=100,mean
age 69.89 years, SD=7.88, 56% male), with no clinical evidence of
PD. All were of Caucasian origin.
At baseline, all subjects underwent cognitive assessment; global
cognitive function was assessed using the mini-mental state
examination (MMSE) [15] and the Montreal Cognitive Assess-
ment (MoCA) [10]. Attention was measured using Cognitive Drug
Research (CDR, Goring-on-Thames, UK) computer testing [19].
Memory was assessed using Pattern Recognition Memory (PRM)
and Spatial Recognition Memory (SRM) from the computerized
Cambridge Neuropsychological Test Automated Battery (CANTAB)
battery [14,20].
MCI was determined using published criteria (using 1.5 SD as
a cut-off) [20]. Highers scores represent worse performance and
directly reﬂect the ability to maintain concentration to a particular
task, conversely greater scores in SRM and PRM represent better
performance [6,19].
2.2. Molecular studies
The entire coding region of C1QA, C1QB and C1QC was
sequenced and compared between UK community PD cases
(n=158) and matched controls (n=100). Sequencing was per-
formed using BDT v3 sequencing chemistry and an ABI3130xl
Genetic Analyser (Applied Biosystems).
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2.3. Statistical power
Power estimatesS8 indicate >0.85 power to detect a signiﬁcant
allelic association (MAF=0.05) with alpha an <0.05, given a preva-
lence of 1% and relative risk of a dominant allele >2.2.
Additionally, QTL power estimates [12] indicate 75%> power to
detect genotype: phenotype differences in MMSE, UPDRS, MoCA,
PoA (power of attention), PRM (pattern recognition memory test-
ing) and SRM (spatial recognition memory testing), given a QTL
variance of 0.10 and an allele frequency of 1%.
2.4. Statistical analysis
Case-control allele and genotype comparisons and comparisons
between common C1Q- variants and cognitive functionweremade
using SPSS (v21).
3. Results
3.1. Case-control genotype comparison
Sequence analysis of C1Q- genes identiﬁed several previ-
ously identiﬁed single nucleotide polymorphisms, six in C1QA;
rs149230484, rs17887074, rs41507347, rs180679721, rs20169349,
rs172378 (previously associated with, lupus, breast cancer sur-
vival and polyneuropathy) [1,4,5] and rs180679721 and two in
C1QC; rs15940 and rs140444929. The majority of variants were
rare (MAF<0.01), with only three with a MAF>0.01 (rs172378,
rs172378 and rs15940). Variant prediction (mutationtaster.org)
predicts benign function outcomes, classifying all nine variants
as polymorphic variants (probability =0.998–0.999). Case-control
analysis revealed no direct relationship to the onset of PD,
when comparing genotypes or alleles (Supplementary Table
1). Additionally, we found no signiﬁcant association between
C1Q-A/B/C genotypes and age of onset when compared using Cox-
proportional hazards model. Additionally, multi-marker analysis
of non-synonymous variants (rs149230484), invoked through the
Cumulative Minor Allele Test (CMAT) [23], failed to ﬁnd a signiﬁ-
cant association between rare-variant burden and PD. Analysis of
C1QB sequence revealed no genetic variation in cases or controls.
3.2. C1Q and baseline cognitive function
Priori comparisons of cognitive assessment between PD cases
and controls revealed signiﬁcant differences in mean MMSE
(P=2.0×10−2), MoCA (P=2.5×10−5), PoA (P=1.0×10−4) PRM
(P=6.0×10−3) and SRM (P=1.0×10−3) scores. Comparison of MCI
status (presence/absence) was signiﬁcantly different between PD
cases and controls (P=1.410−3).
VariantswithMAF>0.01 (rs15940 and rs172378)were selected
for further analysis and compared to mean baseline cognitive
assessment variables (Table 1). We found no signiﬁcant associa-
tion between rs15940(C1QA) genotypes and any baseline variable
(Table1). Additionally,we foundno signiﬁcant associationbetween
rs172378(C1QC) genotypes and MMSE, PoA and SRM. However,
we did ﬁnd a signiﬁcant difference in the mean UPDRS scores
of PD patients when compared to rs15940 (C1QC) genotype
(P=1.8×10−2, Table 1) and the mean MoCA score of controls
whencompared to rs15940 (C1QC) genotype (P= .9×10−2, Table1),
although correcting formultiple testing removed the statistical sig-
niﬁcance of these observations.
3.3. C1Q and MCI
Binary logistic regression comparing cognitively normal (CN) to
mildly cognitive impaired (MCI), with age and gender as covariates,
failed to ﬁnd a signiﬁcant association to either rs15940 (C1QA) or
rs172378 (C1QC)when analysed in just PD cases (rs15940 P=0.640,
rs172378 P=0.985), just controls (rs15940 P=0.384, rs172378
P=0.059) or combined (rs15940 P=0.637, rs172378 P=0.757).
4. Discussion
Our results indicate that C1Q-A/B/C genotypes do not have a
strong effect on the progression of PD but, more importantly, do
not affect cognitive decline when compared to several baseline
measurements of cognitive function. Previouswork has shown that
complement activation occurs in the substantia nigra of PDpatients
[9] and variation in C1Q-A/B/C genetic variation has been shown to
affect neuronal function [5]. However, despite a strong association
between C1Q/cognitive decline and PD/cognitive decline we were
unable to ﬁnd a link between C1Q-A/B/C variation and PD.
4.1. How do we rationalise our results?
Our sequence analysis indicates that C1Q-A/B/C is highly con-
served. We were able to identify several, previously reported,
variants, however only three had aMAF>0.01 (rs172378, rs172378
and rs15940). Taking the signiﬁcantly higher population frequency
of PD, and the benign functional prediction of the C1Q-A/B/CC vari-
ants, we conclude that they are unlikely to be dominant causes of
PD. Multi-locus analysis, useful in assessing the effect of very rare
alleles, failed to identify a signiﬁcant burden in C1Q-A, however
this is likely a result of the high conservation, which result in a low
number ofmeasurable variants and is consistentwith other studies
using small sample sizes [8].
Another possible reason for our lack of association may be PD
disease progression. If the effect of C1Q-A/B/C genotype on PD
is weak in healthy individuals, then it may be masked in a PD
cohort whose attention capacity is already markedly reduced due
to disease itself. Accepting these limitationswe conclude that com-
mon genetic variation in C1Q-A/B/C is unlikely to contribute to the
pathology or cognitive decline seen in PD. However, wewould rec-
ommend that a, larger, longitudinal study following the effects of
cognitivedecline andC1Q-A/B/Cmaybewarranted, given that these
patients exhibit MCI. Moreover, a larger study could identify rare,
pathogenic variants which affect the aetiology of PD which are
beyond the power of this study.
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